MINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.323
EU - Europa 18.925
AS - Asia 16.792
SA - Sud America 2.408
AF - Africa 429
OC - Oceania 318
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 67.202
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.997
RU - Federazione Russa 6.991
SG - Singapore 4.664
CN - Cina 4.400
PL - Polonia 3.861
HK - Hong Kong 2.325
BR - Brasile 1.946
IE - Irlanda 1.848
IT - Italia 1.768
KR - Corea 1.710
VN - Vietnam 1.675
SE - Svezia 1.096
DE - Germania 737
FI - Finlandia 642
FR - Francia 641
IN - India 566
UA - Ucraina 460
GB - Regno Unito 382
JP - Giappone 341
AU - Australia 308
JO - Giordania 253
AR - Argentina 195
CA - Canada 162
ID - Indonesia 157
BD - Bangladesh 137
TR - Turchia 124
MX - Messico 97
NG - Nigeria 92
ES - Italia 90
IQ - Iraq 90
EC - Ecuador 87
CH - Svizzera 86
ZA - Sudafrica 82
NL - Olanda 79
CI - Costa d'Avorio 63
AT - Austria 56
BE - Belgio 52
CO - Colombia 46
MA - Marocco 43
PK - Pakistan 42
TH - Thailandia 38
VE - Venezuela 35
CL - Cile 31
PH - Filippine 30
SA - Arabia Saudita 28
EG - Egitto 27
BJ - Benin 26
AE - Emirati Arabi Uniti 25
PY - Paraguay 25
UZ - Uzbekistan 25
PE - Perù 24
LT - Lituania 18
NP - Nepal 18
KE - Kenya 17
MY - Malesia 17
TN - Tunisia 17
TW - Taiwan 17
SC - Seychelles 16
AL - Albania 15
CZ - Repubblica Ceca 15
DZ - Algeria 15
DO - Repubblica Dominicana 13
IL - Israele 13
UY - Uruguay 13
IR - Iran 11
JM - Giamaica 11
LB - Libano 11
RS - Serbia 11
SY - Repubblica araba siriana 11
AZ - Azerbaigian 10
ET - Etiopia 10
GR - Grecia 10
KZ - Kazakistan 10
NZ - Nuova Zelanda 10
CR - Costa Rica 9
OM - Oman 8
HN - Honduras 7
PT - Portogallo 7
BG - Bulgaria 6
DK - Danimarca 6
PA - Panama 6
RO - Romania 6
TT - Trinidad e Tobago 6
GE - Georgia 5
LV - Lettonia 5
MD - Moldavia 5
MK - Macedonia 5
NO - Norvegia 5
PS - Palestinian Territory 5
BO - Bolivia 4
BY - Bielorussia 4
EU - Europa 4
HU - Ungheria 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BB - Barbados 3
BH - Bahrain 3
CY - Cipro 3
GT - Guatemala 3
HR - Croazia 3
Totale 67.143
Salva come PNG Salva come JPEG
Città #
Santa Clara 6.001
Warsaw 3.830
Singapore 3.381
Ashburn 2.960
Fairfield 2.104
Hong Kong 1.859
Dublin 1.839
Seoul 1.655
Chandler 1.603
Hefei 1.369
San Jose 1.044
Woodbridge 970
Cambridge 869
Seattle 869
Houston 805
Wilmington 759
Jacksonville 687
Beijing 649
Ho Chi Minh City 540
Ann Arbor 453
The Dalles 443
Lauterbourg 430
Los Angeles 425
Buffalo 424
Princeton 382
Hanoi 372
Altamura 366
Lawrence 357
Florence 333
Tokyo 327
Helsinki 316
Moscow 304
Dallas 302
Boston 297
Melbourne 289
Mumbai 285
New York 214
Boardman 206
Shanghai 205
Council Bluffs 194
Munich 194
Kent 190
São Paulo 167
Medford 164
San Diego 134
Clifton 105
Paris 97
Bremen 88
Jakarta 85
Abuja 84
Da Nang 83
West Jordan 78
Milan 77
Redondo Beach 77
Bengaluru 75
Bern 75
Falls Church 74
Guangzhou 74
Turku 73
Haiphong 67
London 67
Phoenix 67
Toronto 65
Abidjan 63
Rome 62
Norwalk 61
Rio de Janeiro 61
Dearborn 60
Frankfurt am Main 59
Orem 57
Dong Ket 56
Chennai 54
Pune 53
Izmir 52
Chicago 49
Belo Horizonte 48
Hillsboro 48
Brussels 44
Vienna 44
Johannesburg 43
Tianjin 37
Barcelona 35
Brooklyn 35
Denver 34
Montreal 33
Auburn Hills 32
Baghdad 32
Biên Hòa 32
Yubileyny 31
Bangkok 29
Guayaquil 28
San Francisco 27
Atlanta 26
Cotonou 26
Andover 25
Curitiba 25
Dhaka 25
Poplar 24
Shenzhen 24
Tashkent 24
Totale 44.475
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 402
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 377
Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy 364
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents. 353
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 351
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 347
Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor 346
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 345
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 345
Solution Chemistry and Cytotoxic Properties of Novel Organogold(III) Compounds 342
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 334
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 331
Natural compounds for cancer treatment and prevention 330
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 327
Emerging drugs in refractory colorectal cancer 327
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 327
The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. 325
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 316
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 314
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 309
Druggable Targets in Pancreatic Adenocarcinoma 305
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 304
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 303
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 301
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 290
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 279
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 264
Mutations of the APC gene in human sporadic colorectal cancers. 251
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 247
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 243
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 243
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 242
[Medical therapy of malignant melanoma] 238
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 231
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 230
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 225
Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters 223
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 222
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 218
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. 218
Cellular pharmacology of gemcitabine. 218
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 213
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 212
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm) 209
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 209
N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors 208
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 206
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 205
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 204
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. 200
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 200
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 199
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 196
Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs) 195
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 195
New structure–activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR) 194
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. 194
Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids 193
LIPOSOMES LOADED WITH BERBERINE HYDROCHLORIDE: DEVELOPMENT, OPTIMISATION AND IN VITRO CITOTOXICITY 193
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 193
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 191
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 190
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 190
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). 189
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 189
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study 187
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 186
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 185
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 185
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. 183
Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 183
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 180
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 180
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 180
Pharmacogenetics: Implementing personalized medicine 179
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 177
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 176
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 176
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 176
Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs 175
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 174
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. 174
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 174
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 172
Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity 171
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations 171
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 171
Inflammation in Urological Malignancies: The Silent Killer 170
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 170
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 169
Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin 169
5-methyltetrahydrofolate (mTHF) induces monocytes differentiation in HL60 cells 168
Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors 168
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 167
The clinical role of PIK3CA mutations in colorectal cancer 166
AN UPDATE ON PERMEATION OF PROTECTIVE MEDICAL GLOVES BY ANTINEOPLASTIC DRUGS 165
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 165
Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation. 164
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 163
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 161
Totale 22.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 189.919
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 189.919
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021514 0 0 0 0 0 0 0 0 0 0 219 295
2021/20222.368 70 224 104 99 78 160 85 212 144 102 403 687
2022/20237.370 607 1.087 244 652 631 1.473 976 451 837 51 174 187
2023/20243.071 137 286 537 118 195 449 174 664 67 185 137 122
2024/202518.969 804 2.152 1.154 2.844 5.115 2.425 278 774 1.096 481 821 1.025
2025/202621.792 2.588 3.610 2.842 2.734 2.235 776 2.700 1.076 1.458 1.245 528 0
Totale 67.812